#CFO #Norway #Oslo #Photocure ASA #Dennis Camporeale

Photocure ASA Appoints Dennis Camporeale as Chief Financial Officer

On October 22, 2026, Photocure ASA, a leading company in bladder cancer diagnostics, announced the appointment of Dennis Camporeale as the new Chief Financial Officer (CFO), effective October 26, 2026. This transition comes as the company seeks to bolster its leadership with a seasoned professional who brings a wealth of experience in the healthcare sector.

Dennis Camporeale is no stranger to navigating the complexities of the healthcare finance landscape, possessing over 25 years of deep experience in healthcare investment banking and corporate finance. He has held significant leadership roles and was most recently the head of the Life Science Tools and Diagnostics division at Canaccord Genuity. In this capacity, he provided strategic advice to boards and C-suite executives on essential aspects of capital raising, mergers and acquisitions, and operational restructuring.

A notable achievement in Camporeale's career includes his tenure at Ally Financial, where he played a pivotal role in transforming GMAC from a captive finance subsidiary into an independent publicly traded company. His contributions were vital in steering the company through its successful IPO, facilitating international divestitures, and establishing robust financial controls and governance frameworks essential for public companies.

Dan Schneider, CEO of Photocure ASA, expressed his enthusiasm about bringing Dennis on board, stating, "I am delighted to welcome Dennis to Photocure as our new CFO. His experience across medtech and diagnostics brings a valuable combination of industry insight and financial acumen that aligns perfectly with our growth strategy. As we focus on unlocking the full potential of our innovative portfolio, Dennis’ insight will be instrumental in executing our vision and generating long-term value for our stakeholders."

Photocure ASA is dedicated to advancing uro-oncology precision diagnostics, harnessing unique technologies that ensure better outcomes for patients with urological cancers. The company is committed to developing transformative solutions that assist healthcare professionals by providing timely diagnostic information, promoting more personalized treatment approaches for their patients. Headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO), Photocure continues to make strides in the healthcare sector, driving significant advancements in bladder cancer diagnostics.

With Camporeale at the helm of the financial strategy, Photocure ASA aims to enhance its operational framework to better navigate the evolving healthcare landscape and expand its influence and capabilities in delivering cutting-edge diagnostic solutions.

In summary, the appointment of Dennis Camporeale as CFO is timely and critical as Photocure ASA embarks on a mission to extend its market reach and innovate its product offerings for the benefit of patients, partners, and shareholders alike. The company has outlined its commitment to growth and excellence in delivering precise diagnostic solutions that make a meaningful difference in the lives of those affected by urological cancers. As they gear up for the future, all eyes will be on how these new leadership changes unfold in shaping the company’s trajectory in the healthcare industry.